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Abstract
Background: Rod-cone dystrophies are heterogeneous group of inherited retinal disorders both clinically and
genetically characterized by photoreceptor degeneration. The mode of inheritance can be autosomal dominant,
autosomal recessive or X-linked. The purpose of this study was to identify mutations in one of the genes, PRPF31,
in French patients with autosomal dominant RP, to perform genotype-phenotype correlations of those patients, to
determine the prevalence of PRPF31 mutations in this cohort and to review previously identified PRPF31 mutations
from other cohorts.
Methods: Detailed phenotypic characterization was performed including precise family history, best corrected
visual acuity using the ETDRS chart, slit lamp examination, kinetic and static perimetry, full field and multifocal ERG,
fundus autofluorescence imaging and optic coherence tomography. For genetic diagnosis, genomic DNA of ninety
families was isolated by standard methods. The coding exons and flanking intronic regions of PRPF31 were PCR
amplified, purified and sequenced in the index patient.
Results: We showed for the first time that 6.7% cases of a French adRP cohort have a PRPF31 mutation. We
identified in total six mutations, which were all novel and not detected in ethnically matched controls. The
mutation spectrum from our cohort comprises frameshift and splice site mutations. Co-segregation analysis in
available family members revealed that each index patient and all affected family members showed a
heterozygous mutation. In five families incomplete penetrance was observed. Most patients showed classical signs
of RP with relatively preserved central vision and visual field.
Conclusion: Our studies extended the mutation spectrum of PRPF31 and as previously reported in other
populations, it is a major cause of adRP in France.
Background
Rod-cone dystrophies, also called retinitis pigmentosa
(RP), are a clinically and genetically heterogeneous
group of inherited retinal disorders usually primarily
affecting rods with secondary cone degeneration [1-4]. It
represents a progressive disorder which often starts with
night blindness and leads to visual field constriction,
abnormal color vision and can eventually lead to loss of
central vision and complete blindness. It is the most
common inherited form of severe retinal degeneration,
with a frequency of about 1 in 4000 births and more
than 1 million individuals affected worldwide. The mode
of inheritance can be X-linked (5-15%), autosomal
dominant (30-40%) or autosomal recessive (50-60%).
The remaining patients represent isolated cases for
which the inheritance trait cannot be established [5].
To date, mutations in 20 different genes are associated
with autosomal dominant RP (adRP) http://www.sph.
uth.tmc.edu/Retnet/. The majority of prevalence studies
reveal rhodopsin (RHO)b e i n gt h em o s tf r e q u e n t l y
mutated gene in adRP [6]. PRPF31 was also proposed to
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located on chromosome 19q13.42, encompasses 14
exons and codes for a ubiquitously expressed pre-
mRNA splicing factor [7]. According to published
reports, PRPF31 mutation prevalence ranges from 1 to
8% in adRP cohorts from various geographical origins,
with higher frequencies reported in the United States
[8-15].
To date over 40 mutations have been located in differ-
ent parts of the gene. The mutation spectrum comprises
missense, splicing, regulatory and nonsense mutations.
In addition small or gross insertions, small insertion-
deletions, and small or gross deletions were identified
(http://www.sph.uth.tmc.edu/Retnet/, http://www.retina-
international.org/sci-news/prp31mut.htm) (Table 1).
The phenotype, age of onset and the severity of the
disease in adRP patients varied with different PRPF31
mutations. In addition, in some families the same muta-
tion was even associated with a range of phenotypic var-
iations [15]. Furthermore, several studies revealed that
incomplete penetrance is a common feature in families
showing PRPF31 mutations with an asymptomatic muta-
tion carrier having a carrier child, who fully manifests
the disease [16-18].
Our comprehensive study reported here aims to per-
form for the first time genotype-phenotype correlations
in a French adRP cohort with PRPF31 mutations. All
patients were recruited from the same clinical center,
namely the Quinze-Vingts hospital in Paris. We will pre-
s e n tt h ep r e v a l e n c eo fPRPF31 mutations in this cohort
and compare our findings with other studies.
Methods
Clinical assessment
Ninety families with a provisional diagnosis of autoso-
mal dominant rod-cone dystrophy, (adRP) were ascer-
tained in the Clinical Investigating Centre of Quinze-
Vingts Hospital. Informed consent was obtained from
each patient and normal controls after explanation of
the study and its potential outcome. The study protocol
adhered to the tenets of the Declaration of Helsinki and
was approved by the local ethics committee. Each
patient underwent full ophthalmic examination with
clinical assessment as described earlier [6]. For addi-
tional family members who could not come to our cen-
tre for examination, ophthalmic records were obtained
from local ophthalmologists.
Mutation detection
Total genomic DNA was extracted from peripheral
blood leucocytes according to manufacturer recommen-
dation (Puregen Kit, Qiagen, Courtaboeuf, France). Sub-
sequently, direct genomic sequencing of PRPF31 was
performed. All 14 exons of which exons 2-14 are coding,
and flanking intronic regions of PRPF31 were PCR
amplified in 10 fragments (PRPF31 RefSeq NM_015629)
using oligonucleotides previously described [7] and a
polymerase (HotFire, Solis Biodyne, Estonia) in the pre-
sence of 2.5 mM MgCl2 and at an annealing tempera-
ture of 60°C. The PCR products were enzymatically
purified (ExoSAP-IT, USB Corporation, Cleveland, Ohio,
USA purchased from GE Healthcare, Orsay, France) and
sequenced with a commercially available sequencing
mix (BigDyeTerm v1.1 CycleSeq kit, Applied Biosystems,
Courtaboeuf, France). The sequenced products were
purified on a presoaked Sephadex G-50 (GE Healthcare)
96-well multiscreen filter plate (Millipore, Molsheim,
France), the purified product analyzed on an automated
48-capillary sequencer (ABI 3730 Genetic analyzer,
Applied Biosystems) and the results interpreted by
applying a software (SeqScape, Applied Biosystems). At
least 192 commercially available control samples were
used to validate the pathogenicity of the novel sequence
variants (Human random control panel 1-3, Health Pro-
tection Agency Culture Collections, Salisbury, United
Kingdom).
Multiplex Ligation dependent Probe Amplification
(MLPA) was performed using a commercially available
kit (SALSA MLPA kit P235-B1 Retinitis, MRC Hol-
land). The MLPA reactions were carried out according
to the manufacturer’s instructions and analyzed on an
automated 48-capillary sequencer (ABI 3730 Genetic
analyzer, Applied Biosystems). MLPA data analysis was
performed using GeneMarker (Softgenetics) and addi-
tionally Coffalyser (MRC Holland) software. Five con-
trol DNAs were included in each MLPA run and the
data was interpreted in terms of the ratio of each
probe signal between the control and patient DNA
samples. Samples with probe ratio values below 0.6
were considered as deletions and values above 1.4 as
duplications.
Results and Discussion
Samples included in this study are part of a French
cohort of adRP patients that were previously screened
for RHO mutations and we noted 16.5% of cases with
known or novel RHO mutations [6].
In the current study we report the identification of
novel PRPF31 mutations in six of the 90 adRP index
patients. In total two deletions, three duplications and a
splice site mutation all over the gene were identified
(Table 2). The respective deletions and duplications
were predicted to lead to premature stop codons. The
novel splice site mutation c.527 + 2T>C resides in the
highly conserved donor site of exon 6, which is pre-
dicted to lead to skipping of exon 6. Co-segregation
analysis revealed in all but one family incomplete pene-
trance (Table 2, Figure 1).
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Page 2 of 9Table 1 Previously described PRPF31 mutations in adRP patients
Exon/Intron Nucleotide Exchange Protein Effect Publication Information
about
penetrance
Int1 c.1-2481G>T (formerly: IVS1
+1G>T)
splice defect [27] incomplete
2 c.79G>T p.Glu27X [15] Incomplete
Int2 c.177+1G>A splice defect [13]
[23]
Simplex
Simplex
3 c.220C>T p.Gln74X2 [13] Simplex
4 c.319C>G p.Leu107Val (interferes with splice site leading to
frameshift)
[23] Simplex
Int4 c.323-2A>G Splice defect [23] Simplex
5 c.331_342del p.His111_Ile114del [22] High
5 c.358_359delAA p.Lys120GlufsX122 [9] Simplex
5 c.390delC p.Asn131MetfsX67 (formerly p.Asn131fs7ter197) [13] segregates in 3
affected
5 c.413C>A (formerly
c.412C>A)
p.Thr138Lys [15] Incomplete
Int5 c.421-1G>A splice defect [28] Incomplete
6 c.421G>T p.Glu141X [13] Simplex
Int6 c.527+1G>T splice defect [29] Incomplete
Int6 c.527+1G>A splice defect [9] Incomplete
Int6 c.527+3A>G splice defect [7,16]
[15]
Incomplete
incomplete
Int6 c.528-1G>A splice defect [15] not tested
Int6 c.528-3_45del (previous
description: IVS6-3 to -45
del)
splice defect [7,12] Incomplete
7 c.581C>A p.Ala194Glu [7] Simplex
7 Formerly: 580-581dup33bp formerly: in frame insertion of 11 amino acids [7] Simplex
7 c.636delG p.Met212IlefsX27 (formerly: Met212fs/ter238) [13] segregates in 2
affected
7 c.646G>C p.Ala216Pro [7] Incomplete
8 c.732_737delins20bp p.Met244fsX248 [11] segregated in 2
affected
8 c.758_767del p.Gly253AlafsX65 (formerly: p.Gly253fs/ter317) [13] Simplex
8 c.769_770insA p.Thr258AspfsX21 (formerly: frameshift, 20 novel
amino acids then STOP) (formerly:Lys257fsX277)
[7]
[11]
Simplex
incomplete
8 c.785delT p.Phe262SerfsX59 [10]
8 c.828_829delCA p.His276GlnfsX2 (formerly p.His276fsX237) [11] Incomplete
Int8 c.856-2A>G splice defect [23] segregated in 2
affected
9 c.871G>C p.Ala291Pro [13] Simplex
9 c.877_910del p.Arg293_Arg304>ValfsX17 [23] Incomplete
9 c.895T>C p.Cys299Arg [13] Incomplete
10 c.973G>T p.Glu325X [13] Simplex
10/int10 1049_IVS10+20del/insCCCCT splice defect [13] Simplex
Int10 c.1073+1G>A (Formerly:
IVS10+1G>A)
splice defect [13] segregates in 5
affected
11 c.1115_1125del p.Arg372GlnfsX99 (formerly: frameshift, 98 novel
amino acids then STOP)
[7] Incomplete
11 c.1142delG p.Gly381GlufsX32 [12] Incomplete
Int11 c.1146+2T>C Splice defect [15] Incomplete
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patients) where no mutations was detected by direct
sequencing approaches, MLPA studies were performed.
However, no additional deletion was found by this
method.
Phenotypic characteristics of the 6 index patients are
summarized in table 3 and 4. Four of them were females
and two males with age ranging from 23 to 44 years
with an average age of 34.5 years. Age at time of diagno-
sis ranged from 5 to 43 with an average of 19.5 years.
Symptoms that led to the diagnosis were dominated by
night blindness in all patients but one (CIC01171). Two
patients also complained of visual field constrictions
(CIC00034 and CIC01171). Refractive errors were vari-
able. Central visual acuity was relatively preserved
except in one patient (CIC00140), age 31, who had
decreased central vision that just qualified her for legal
blindness. Preserved central vision was well correlated
with preserved responses to central hexagons in multifo-
cal ERG. All patients showed visual field constriction
with some peripheral perception, except for one patient
(CIC00607), age 23, who had a relatively normal binocu-
lar visual field. This patient was the only one with
detectable responses for both scotopic and photopic
condition on ERG. Color vision was normal in 3
patients or showed tritan defect in one eye for one
patient (CIC00607) and both eyes for patients CIC00140
and CIC03777 who also had low visual acuity. Anterior
segment examination showed moderate posterior sub-
capsular cataract only in one patient (CIC00034), age
42. Fundus examination showed typical peripheral signs
of RP with variable posterior pole involvements (Figure
2) including one patient with cystoid macular edema
(CIC00607, Figure 2B), one patient with an area of par-
afoveal well-demarcated atrophy (CIC00034, Figure 2C),
two patients with perifoveal atrophic changes
(CIC01171, Figure 2D, CIC03777, Figure 2F) and one
patient with foveal thinning (CIC00140, Figure 2E). This
would suggest that central involvement is not uncom-
mon in the course of the disorders and that central
changes can occur as early as age 31 (patient CIC00140,
Figure 2E). These cone dysfunction and macular
changes can lead to further decrease in central vision
and central cone survival should be the major target of
future therapeutic intervention.
Due to the small number of index patients included in
this study, it is difficult to draw general conclusions on
phenotypic variability and phenotype/genotype correla-
tion. However, our cohort still shows on one hand one
patient with reduced but still detectable rod-cone
Table 1 Previously described PRPF31 mutations in adRP patients (Continued)
12 c.1155_1159delGGACG/
insAGGGATT
p.Asp386GlyfsX28 [12] Incomplete
Int13 c.1374+654C>G Splice defect [19] Incomplete
ex1/int1 indel ex1/int1 Loss of one copy of PRPF31 [14] Incomplete
4-8 4.8 kb deletion Loss of one copy of PRPF31 [14] simplex
4-13 11.3 kb deletion Loss of one copy of PRPF31 [14] incomplete
PRPF31: 1-11, TFPT, NDUFA3,
partly OSCAR
59 kb deletion Loss of one copy of PRPF31 [30] incomplete
PRPF31, TFPT, NDUFA3, partly
OSCAR
32-42 kb deletion Loss of one copy of PRPF31 [14] simplex
PRPF31, TFPT, NDUFA3, OSCAR > 44.8 kb deletion Loss of one copy of PRPF31 [14] simplex
PRPF31 without Stop codon,
TFPT NDUFA3, promoter OSCAR
30 kb deletion Loss of one copy of PRPF31 [31] incomplete
If possible, mutations are indicated according to NM_015629 by using the recommendations of human genome variation society: http://www.hgvs.org/rec.html
and/or the nomenclature of the original publication are given.
Table 2 Novel PRPF31 mutations in a French adRP cohort.
Index (families) Exon Nucleotide Exchange Protein Effect Information about Penetrance
CIC00398 (F273) 4 c.269_273del p.Tyr90CysfsX21 incomplete
CIC00607 (F405) Int6 c.527+2T>C splice defect incomplete
CIC00034 (F28) 7 c.666dup p.Ile223TyrX56 segregates (1 affected show mutation, 3 unaffected no mutation)
CIC03777 (F1706) 8 c.709_734dup p.Cys247X incomplete
CIC01171 (F700) 9 c. 873_897dup p.Thr300GlyfsX32 incomplete
CIC00140 (F108) 10 c.997delG p.Glu333SerfsX5 incomplete
Mutations are indicated according to NM_015629.3 by using the recommendations of human genome variation society: http://www.hgvs.org/rec.html.
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at age 23 and on the other hand one legally blind
patient with undetectable ERG (CIC00140), at age 31,
suggesting variable severity of the disorder. This variable
severity of the disorder is in accordance with previous
r e p o r t s ,w h i c ha l s om e n t i o n e dt h ep o s s i b l er o l eo f
unknown modifier genes [15]. Further longitudinal stu-
dies are required to document retinal degeneration
kinetics and especially macular involvement in order to
prepare the patients for future treatment.
With the study presented here we report 6 novel
mutations in a French cohort leading to variable severity
of adRP. To our knowledge, this is the first report on
PRPF31 mutation screening and prevalence in the
French population and it further expands the mutation
spectrum causing adRP. In total two deletions, three
duplications and a splice site mutation were identified
(Table 2). To date only few PRPF31 variations have
been reported to be recurrent (Table 1). This holds also
true for our study. Consistent with previous reports, we
propose that these mutations also lead to loss of func-
tion of PRFP31 and thus to haploinsufficiency [19-21].
In five of our families incomplete penetrance was
observed. Only in one family (family 28) no asympto-
matic mutation/or obligate carriers were reported. This
was confirmed on three unaffected family members who
did not reveal a mutation. However, due to the small
size of the family, incomplete penetrance cannot be for-
mally excluded for this mutation. To our knowledge, to
date only one large Chinese family was reported with
high penetrance [22], sugg e s t i n gt h a tm o s to ft h e
PRPF31 mutations are indeed associated with incom-
plete penetrance. Although the presumed mechanism to
explain this phenomenon is allelic imbalance with over-
Figure 1 Pedigrees of adRP patients with PRPF31 mutations and co-segregation in available family members. Filled symbols represent
affected, unfilled unaffected and dotted asymptomatic individuals. Question marks indicate that it is not clear whether the individual is affected
or not. Squares depict males, circles females. Arrows mark the index patients. Equation symbols represent unaffected alleles. The identified
mutations were abbreviated as followed: A = c.269_273del, B = c.527+2T>C, C = c.666dup, D = c.709_734dup, E = c.873_897dup and F =
c.997delG.
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Page 5 of 9Table 3 Clinical data of affected members from families with adRP due to PRPF31 mutations
Family
and
PRPF31
mutation
Patient Age at
time
of
testing
Age at
time of
diagnosis
Sex Family history Symptoms
at time of
diagnosis
BCVA OD/OS
Refraction
Lens Fundus examination OCT FAF
F273 CIC398 23 5 M From North of Brittany
Father affected and few
Night
blindness
20/25
20/20
-6.25(-1.75)20°
-5.50(-1.25)175°
clear Normal disc color,
narrowed retinal vessels,
little RPE changes in the
periphery,
Preserved
foveal
lamination
Loss of AF outside the
vascular arcades, perifoveal
ring of increased AF
F405 CIC00607 23 20 F One sister affected, cousins
on maternal side affected
Mother not affected
incomplete penetrance
From French descent
Night
blindness
late teens
20/32
20/32
+0.75(-2.75)15°
Plano(-1.75)175°
clear Bilateral ERM Normal disc
color; no narrowing of
blood vessels; little
changes in the periphery
with few bone spicules
Bilateral
ERM
Bilateral
CME
Perifoveal ring of increased
AF; foveal changes due to
CME
F28 CIC00034 42 18 F Family from Cameroun,
daughter mother and one
brother affected, no notion
of incomplete penetrance
Night
blindness
and visual
field
constriction
20/32
20/32
-3.25(-0.75)65°
-3.25(-0.75)130°
Small
posterior
subcapsular
opacities
Disc pallor narrowed,
blood vessels, RPE
changes in periphery,
bilateral atrophic lesion
off the fovea
Preserved
foveal
lamination
Loss of AF outside the
vascular arcades, round
eccentric parafoveal area of
loss of AF, no ring of AF
F1706 CIC03777 44 8 F Paternal grand-mother,
great-grand mother and one
great-uncle on father side
affected, French family from
Jewish Ashkenazi ancestry
Night
blindness
since age 7
20/125
20/160
+0.5(-1.25)40°
+0.25(-1.50)155°
pseudophakic Pale optic disc, narrowed
retinal vessels
Preserved
foveal
lamination
Loss of AF outside the
vascular arcades, patchy loss
of AF within the posterior
pole with no ring of AF
F700 CIC01171 44 43 M One elder brother affected,
one niece affected from one
of his unaffected sister, one
uncle on father side
Incomplete penetrance
family originating from the
Mauritius Island
Visual field
constriction,
no real
night
blindness
20/32
20/25
-0.50(-3.75)15°
-0.25(-3.75)175°
clear Normal disc color,
narrowed retinal vessels,
RPE changes in the
periphery
Preserved
foveal
lamination
Loss of AF outside the
vascular arcades; small
perifoveal ring of increased
autofluorescence with some
perifoveal areas of loss of
AF
F108 CIC00140 31 23 F Mother, maternal grand-
mother affected; family from
Ivory Coast
Night
blindness
since birth
20/500
20/200
+1.50(-1.25)95°
+1.50(-1.25)75°
clear No pale optic disc;
narrowed retinal vessels,
some RPE changes in the
periphery
Foveal
thinning
Loss of AF outside the
vascular arcades, increased
AF within the foveal region
associated with some
patchy loss of AF
BCVA Best Corrected Visual Acuity; CME: Cystoid Macular Edema; ERM: Epi Retinal Membrane; AF: autofluorescence; OCT: optic coherence tomography OD: Oculis dextra (right eye); OS: Oculis Sinistra (center eye);
RPE: Retinal Pigment Epithelium.
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9expression of the wild-type allele, compensating for the
non-functional allele in asymptomatic carriers [21,23],
the exact mechanism how this over-expression happens
remains to be solved.
Patient data and mouse in vivo studies strongly sug-
gest that the disease mechanism is caused by
haploinsufficiency rather than dominant negative effect.
A recent study in mice demonstrated that p.A216P
mutation as well as deletion of Prpf31 exon 7 in mice
lead to null alleles [24]. Mice heterozygous for these
mutations did not reveal signs of retinal degeneration in
histological, ERG and fundus examination, however in
Table 4 Functional data.
Patient Color vision Binocular Goldman visual field, III4
isopter
Full field ERG Multifocal ERG
CIC00398 ODS normal at 28
saturated Farnworth
Hue
20° both horizontally and vertically
with a large island of perception in
temporal and inferior periphery
Only residual cone responses Relatively well
preserved central
responses
CIC00607 OD tritan defect; OS
normal at Farnsworth
15Desaturated Hue
180° horizontally ×110° vertically Rod-cone dysfunction with 80% of normal for
scotopic 3.0cd.s/m
2 ERG amplitude and 50% of
normal for photopic 3.0cd.s.m
2
Relatively well
preserved central
responses
CIC00034 ODS normal at 28
saturated Farnworth
Hue
20° both horizontally and vertically
with 2 bitemporal island of perception
in periphery
ND Only preservation
of responses to
central hexagons
CIC03777 ODS tritan defext at 28
saturated Farnworth
Hue
20° both horizontally and vertically ND Only residual
responses to
central hexagons
CIC01171 ODS normal at 28
saturated Farnworth
Hue
20° both horizontally and vertically ND Only preservation
of responses to
central hexagons
CIC00140 ODS tritan defext at 28
saturated Farnworth
Hue
30° both horizontally and vertically
with a large island of perception in
temporal and inferior periphery
ND Only residual
responses to
central hexagons
NP: not performed; ND: not detectable, OD: Oculus Dexter; OS: Oculus Sinister.
Figure 2 Color fundus photograph and autofluorescence imaging of the right eye for each index patient: A: CIC0398; B: CIC00607;
C: CIC00034; D: CIC01171; E CIC00140; F: CIC03777.
Audo et al. BMC Medical Genetics 2010, 11:145
http://www.biomedcentral.com/1471-2350/11/145
Page 7 of 9h o m o z y g o u ss t a t et h e yw e r ee m b r y o n i cl e t h a l ,d e m o n -
strating lack of function of the mutant Prpf31 alleles. In
a number of studies a cytotoxic effect of PRPF31 muta-
tions has been suggested [25,26]. We believe that this
toxicity plays a minor role in the development of the
disease since asymptomatic mutation carriers do not
develop retinal degeneration.
The study presented here reveals a prevalence of 6.7%
in adRP cases due to PRPF31 mutations. This is higher
than in another study from UK with 5% [15], in a study
from India (4%), from Japan with 3% [12], from Spain
with 1.7% [11] and from China with 1% [10]. A preva-
lence study by Sullivan and co-workers (2006) in 200
US families of presumably UK origin revealed 5.5% of
cases with PRPF31 mutations. However, these numbers
were corrected to 8% when MLPA studies revealed lar-
ger deletions, which were not detectable by direct
sequencing approaches [14]. In contrast to these find-
ings, our MLPA studies did not reveal any large dele-
tions or duplications in this cohort. Therefore, we
conclude that genomic rearrangements in the PRPF31
gene are not common in the French adRP cohort.
Conclusions
With the study presented here we report six novel
mutations in a French cohort leading to variable severity
of adRP in families with mainly incomplete penetrance.
In 6.7% of this cohort PRPF31 mutations were detected,
rendering this gene a major gene for adRP in France.
Consistent with previous reports, we propose that muta-
tions in PRPF31 are mainly not recurrent, lead to loss of
function of PRFP31 and thus to haploinsufficiency.
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